Putting The Spotlight On STING & TLR Agonists
Preclinical data has been hugely promising when targeting key signalling components of the innate immune system such as the STING or TLR pathways and in recent months we have seen a huge explosion in investment and development in this field. However, challenges remain in terms of translation, clinical development and optimisation of these innate immune stimulating therapies.
The Innate Immune Stimulating Therapies Summit is dedicated to the safe and effective clinical and commercial translation of STING and TLR therapies. Engage in discussions on how to overcome safety challenges and prevent severe adverse events without compromising on efficacy in the tumor micro-environment.
What Did You Miss?
Explore model selection to drive and direct clinical trial development with H3biomedicine
Improve delivery of innate immune stimulating therapies to overcome efficacy and safety challenges with Mersana and Checkmate Pharmaceuticals
Optimize TLR therapy to accelerate success in clinical trials with GSK
Advance anti-tumor treatments through development of combination therapy approaches with Aduro Biotech and UPMC
Induce anti-tumor immunological memory in both the innate and adaptive immune system to achieve a more consistent immune response with Decoy Biosystems